Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.
Department of Surgery, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
Gastrointest Endosc. 2018 Apr;87(4):1138-1146. doi: 10.1016/j.gie.2017.08.017. Epub 2017 Aug 24.
EUS-guided choledochoduodenostomy (EUS-CDS) using conventional tubular stents has been successfully performed. However, EUS-CDS carries a high risk of bile leakage with attendant adverse events. This study aimed to prospectively evaluate the long-term outcome of EUS-CDS using a dedicated lumen-apposing metal stent (LAMS).
Nineteen patients (mean age, 70.6 years; 12 men) with unresectable malignant diseases were treated in 5 tertiary referral centers. EUS-CDS was performed using a fully covered LAMS with a cautery-enhanced delivery system for EUS-CDS.
All stents were successfully deployed without any adverse events. Jaundice improved in 79% of the patients within 7 days and finally in 95%. In 95% of patients the stents remained in good anastomotic position without migration or dislocation during the follow-up period (median, 184 days; range, 12-819). One patient had a fever the day after stent placement. During the follow-up period 5 patients had secondary stent obstruction because of food residue (n = 2), kinking (n = 1), suspected tumor ingrowth (n = 1), and spontaneous dislodgement (n = 1). Five patients developed obstruction in the second portion of the duodenum. The overall adverse event rate was 36.8% (7/19), mostly with mild severity.
This study revealed that the novel dedicated LAMS used has high technical and clinical success rates for EUS-CDS. The adverse events and patency rates are inferior to the historically reported data of a conventional transpapillary metal stent. Development of a more suitable dedicated LAMS is anticipated.
经超声内镜引导的胆肠吻合术(EUS-CDS)使用传统的管状支架已取得成功。然而,EUS-CDS 存在较高的胆汁漏风险,伴随不良事件。本研究旨在前瞻性评估专用的腔镜吻合金属支架(LAMS)在 EUS-CDS 中的长期疗效。
在 5 家三级转诊中心,19 例(平均年龄 70.6 岁;12 例男性)不可切除的恶性疾病患者接受了 EUS-CDS 治疗。EUS-CDS 使用带有电切增强输送系统的全覆膜 LAMS 进行。
所有支架均成功植入,无任何不良事件。7 天内 79%的患者黄疸改善,最终 95%的患者黄疸改善。在随访期间(中位数 184 天;范围 12-819 天),95%的患者支架仍保持良好的吻合位置,无迁移或脱位。1 例患者在支架放置后 1 天发热。随访期间,5 例患者因食物残渣(n=2)、扭结(n=1)、疑似肿瘤内生长(n=1)和自发性移位(n=1)而出现二次支架阻塞。5 例患者发生十二指肠第二段阻塞。总的不良事件发生率为 36.8%(19/52),多为轻度。
本研究表明,新型专用 LAMS 用于 EUS-CDS 具有较高的技术和临床成功率。不良事件和通畅率不如传统经乳头金属支架的历史报告数据。预计会开发出更合适的专用 LAMS。